AbbVie Inc (ABBV)vsSera Prognostics Inc (SERA)
ABBV
AbbVie Inc
$261.01
+3.99%
HEALTHCARE · Cap: $447.62B
SERA
Sera Prognostics Inc
$2.00
+2.00%
HEALTHCARE · Cap: $70.49M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 110208672% more annual revenue ($62.82B vs $57,000). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
SERA
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.1%
Fair Value
$146.57
Current Price
$261.01
$114.44 premium
Intrinsic value data unavailable for SERA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : SERA
The strongest argument for SERA centers on Price/Book, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : SERA
The primary concerns for SERA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
SERA carries more volatility with a beta of 0.94 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 25/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Sera Prognostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sera Prognostics Inc. is a leading innovator in maternal-fetal health, specializing in advanced diagnostic solutions aimed at improving pregnancy outcomes. The company's flagship PreTRM test leverages a proprietary biomarker platform to accurately assess the risk of preterm birth, allowing healthcare providers to deliver timely and effective interventions. With its commitment to enhancing prenatal diagnostics and addressing critical healthcare needs, Sera is well-positioned for substantial growth in the maternal health market, presenting sustainable value creation opportunities for its investors.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?